Simer Preet Singh, MD
Pain Medicine · Rochester, NYNPI 1942443452
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,476 of the $5,312 with a category attached, or 65.4%. 23 manufacturers reported payments, led by Abbott at 44.4% of the total. Reporting peaked in 2019 at $3,207 and has fallen 87.4% since, to $406 in 2025.
Across 74 payments — averaging $71.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Vertos Medical, Inc.$1K
- Bioventus LLC$741
- Medtronic$543
- Nalu Medical, Inc.$141
- Boston Scientific$84
- plus $390 from 17 others
Across 19 payments — averaging $1340.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$25K
What the payments were for
- Travel & lodging$3,47665%
- Food & beverage$1,81034%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $2,360 |
| Vertos Medical, Inc. | 8 | $1,054 |
| Bioventus LLC | 3 | $741 |
| Medtronic(2 entities) | 10 | $543 |
| Nalu Medical, Inc. | 1 | $141 |
| Boston Scientific | 5 | $84 |
| Braeburn Inc. | 3 | $54 |
| Scilex Pharmaceuticals Inc. | 3 | $43 |
| Novartis | 3 | $36 |
| Pfizer | 2 | $28 |
| Tonix Medicines, Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $26 |
| UCB, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Saluda Medical Americas, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Fidia Pharma USA Inc. | 1 | $11 |
| SPR Therapeutics, Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,312 in reported general payments places this provider in the 75th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $299 |
| Gabapentin | 23 | $201 |
| Celecoxib | 11 | $193 |
| Baclofen | 13 | $122 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Rochester
- John MarkmanRochester$92K
- Armando VillarrealRochester$19K
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$614K
- William CaldwellStony Brook$530K
- Brian DurkinPort Jefferson$455K
- David SpinnerNew York$391K
- Grace FordeNew Hyde Park$355K
- Romanth WaghmaraeHamburg$158K
- Samuel BrownSouthold$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.